ArticleEClinicalMedicine2022

Favipiravir, camostat, and ciclesonide combination therapy in patients with moderate COVID-19 pneumonia with/without oxygen therapy: An open-label, single-center phase 3 randomized clinical trial.

Jiro Terada et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.